NCT04449874 trial: what clinicians have said so far
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- NCT04449874 ↗
- Active, not recruiting
- Genentech, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04449874 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04449874 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors
- Interventions
- GDC-6036; Atezolizumab; Cetuximab; Bevacizumab; Erlotinib; GDC-1971; Inavolisib
- Arms
- Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II) · Experimental
- Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II) · Experimental
- Arm C: GDC-6036 + Cetuximab (Stage I and Stage II) · Experimental
- Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II) · Experimental
- Arm E: GDC-6036 + Erlotinib (Stage I and Stage II) · Experimental
- Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II) · Experimental
- Arm G: GDC-6036 + Inavolisib (Stage I and Stage II) · Experimental
- Enrollment
- 498 (estimated)
- Primary outcomes
- Percentage of Participants With Adverse Events (AEs)
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)
- Sponsor
- Genentech, Inc.
- Start
- Jul 29, 2020
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04449874 · updated Aug 28, 2026
Publications
linked from the registry- Sacher AG, Miller WH Jr, Patel MR, Paz-Ares L, Santoro A, Ahn MJ, Dziadziuszko R, Freres P, Luo J, Bowyer S, Desai J, Markman B, De Miguel M, Deva S, Falcon A, Alonso G, Guedes JD, Kim SH, Krebs MG, Laurie SA, Massarelli E, Medina L, Prenen H, Amatu A, Van Dongen M, Choi Y, Hou X, Qi T, Lin MT, Koli K, Mayo MC, Yau KK, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Lorusso P; GO42144 Investigator Study group; GO42144 Investigator Study Group. Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. J Clin Oncol. 2025 Oct 20;43(30):3249-3253. doi: 10.1200/JCO-25-00040. Epub 2025 Jul 9. PubMed 40632992
- Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. PubMed 38052910
- Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. PubMed 37611121